期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

心肌脂肪酸β-氧化抑制剂研究进展 被引量：2

Recent progress in cardiac muscle fatty acid β-oxidation inhibitor
下载PDF
导出
摘要 本文综述心肌脂肪酸β-氧化抑制剂的药理作用、临床疗效以及此类药物的研究进展,同时介绍了雷诺嗪和盐酸曲美他嗪在我国的研发现状。 This review is focusing on the pharmacology,clinical efficacy and research progress of cardiac muscle fatty acid oxidation inhibitor.Recent research and development progress as well as marketing of ranolazine and trimetazidine hydrochloride in China are especially introduced.
作者 曹健
机构地区 上海旭东海普药业有限公司
出处 《上海医药》 CAS 2011年第5期229-231,共3页 Shanghai Medical & Pharmaceutical Journal
关键词 脂肪酸 β-氧化抑制剂 雷诺嗪 盐酸曲美他嗪 心绞痛 fatty acid oxidation inhibitor ranolazine trimetazidine hydrochloride angina
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献18

  • 1杨莹,薛霞,刘兆平.心肌脂肪酸氧化抑制剂的研究进展[J].齐鲁药事,2008,27(9):549-551. 被引量：1
  • 2Parang P,Singh B,Arora R.Metabolic modulators for chronic cardiac ischemia[J].J Cardiovasc Pharmacol Ther,2005,10(4):217-223.
  • 3Pauly DF,Pepine CJ.Ischemic heart disease:Metabolic approaches to management[J].Clin Cardiol,2004,27(8):439-441.
  • 4Chaitman BR.Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions[J].Circulation,2006,113(20):2462-2472.
  • 5Stone PH,Chaitman BR,Stocke K,et al.The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease[J].J Am Coll Cardiol,2010,56(12):934-942.
  • 6Wang JX,Maruyama K,Murakami M,et al.Antianginal effects of ranolazine in various experimental models of angina[J].Arzneimittelforschung,1999,49(3):193-199.
  • 7Chandler MP,Stanley WC,Morita H,et al.Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure[J].Circ Res,2002,91(4):278-280.
  • 8Nanda S,Martinez MW,Dey T.Ranolazine is effective for acute or chronic ischemic dysfunction with heart failure[J].J Am Coll Cardiol,2010,56(10):822.
  • 9Singh BN,Wadhani N.Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs[J].J Cardiovasc Pharmacol Ther,2004,9(Suppl 1):85-97.
  • 10Zacharowski K,Blackburn B,Thiemermann C.Ranolazine,a partial fatty acid oxidation inhibitor,reduces myocardial infarct size and cardiac troponin T release in the rat[J].Eur J Pharmacol,2001,418(1-2):105-110.

二级参考文献16

  • 1Siddiqui MA,Keam SJ. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs, 2006,66 (5) : 693-710.
  • 2Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail, 2002,8 (6) :416-422.
  • 3Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amLodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized eontrolled trial, JAMA,2004,291(3):309-316.
  • 4Kantor PF,Lucien A,Kozak R,et al. The antianginal drug trimetazldine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long--chain 3-- ketoacyl coenzyme A thiolase. Circ Res, 2000,86 (5) : 580- 588.
  • 5Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina:a meta--analysis of randomized,double--blind, controlled trials. Coron Artery Dis, 2003,14(2) : 171-179.
  • 6Lloyd S, Broeks C, Chatham JC. Differential modulation of glucose,lactate, and pyruvate oxidation by insulin and diehloroacetare in the rat heart. Am J Physiol Heart Circ Physiol, 2003,285 (1):H163.
  • 7Schmitz FJ, Rosen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoy I transferase inhibitor Etomoxir. Horm Metab Res, 1995, 27 (12) :515-522.
  • 8Schmidt--Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) ,2000,99(1) :27-35.
  • 9Kennedy JA, Unger SA, Horowitz JD. Inhibition of earnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol, 1996,52(2) : 273-280.
  • 10Stewart S, Voss DW, Northey DL, et al. Relationship between plasma perhexiline concentration and symptomatic stalus during short-- term perhexiline therapy. Ther Drug Monit, 1996, 18 (6):635-639.

同被引文献12

  • 1Creager M A, White C J, Hiatt W R, et al. Atherosclerotic peripheral vascular disease symposium II executive summary [J]. Circulation, 2008,118(25) : 2811-2825.
  • 2Fragasso G, Perseghin G, De Cohelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphoereatine/adenosine triphosphate ratio in patients with heart failure [J]. Eur Heart J, 2006,27(8) :942-948.
  • 3Hu B, Li W, Xu T, et al. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials [J]. Clin Cardiol, 2011,34(6) :395-400.
  • 4Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease [J]. Eur Heart J,2004,25 (20) : 1814-1821.
  • 5Belardinelli R, Lacalaprice F, Faccenda E,et al. Clinical benefits of a metabolic approach in the cardiac rehabilitation of patients with coronary artery disease [J]. Am J Cardiol, 2006, 98 (5A) : 25J-33J.
  • 6Rosano G M, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease [J].Am J Cardiol, 2006,98(5A) :14J-18J.
  • 7Fragasso G, Piatti Md PM, Monti L, et al. Short and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy [J]. Am Heart J, 2003,146(5):E18.
  • 8严凤娣,何胜虎,张晶,燕建锋,陈述.人血管内皮细胞的氧化损伤及药物保护作用的研究[J].实用医学杂志,2008,24(15):2587-2589. 被引量：6
  • 9杨登云.曲美他嗪治疗冠心病心力衰竭92例临床观察[J].中国现代药物应用,2011,5(10):102-103. 被引量：3
  • 10张惠芳,刘金霞,刘大成,王晨晨,张海霞,刘树静,丰超.曲美他嗪治疗80岁以上高龄老人冠心病心力衰竭的临床观察[J].河北医学,2011,17(7):944-947. 被引量：16

引证文献2

二级引证文献3

上海医药
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部